<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00777452</url>
  </required_header>
  <id_info>
    <org_study_id>SMC IRB 2004-05-21</org_study_id>
    <secondary_id>CRS104-10-4</secondary_id>
    <nct_id>NCT00777452</nct_id>
  </id_info>
  <brief_title>A Prospective Longitudinal Study of Health-Related Quality of Life in Men With Clinically Localized Prostate Cancer</brief_title>
  <official_title>A Prospective Quality of Life Study in Men With Clinically Localized Prostate Carcinoma Treated With Different Treatment Modalities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      to prospectively assess the health-related quality of life (HRQOL) changes during the first
      year after different treatment modalities for localized prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Quality of life is of great concern to patients considering treatment options for prostate
      cancer. Patients with clinically localized prostate cancer treated with active surveillance,
      radical prostatectomy, external radiotherapy and high intensity focused ultrasound were
      included. All men completed the questionnaires of Functional Assessment of Cancer
      Therapy-Prostate (FACT-P) (version 4), International Prostate Symptom Score (IPSS) and
      International Index of Erectile Function (IIEF) before treatment and 1, 3, 6, 12 months after
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Health-related quality of life changes over time</measure>
    <time_frame>12 months after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>urinary symptom score and erectile function over time</measure>
    <time_frame>12 months after treatment</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">93</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>active surveillance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>radical prostatectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>external beam radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <description>high intensity focused ultrasound</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients with clinically localized prostate cancer at single tertiary institution
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients diagnosed with clinically localized prostate cancer

        Exclusion Criteria:

          -  patients with another malignancies
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>43 Years</minimum_age>
    <maximum_age>82 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Han Yong Choi, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Hashine K, Kusuhara Y, Miura N, Shirato A, Sumiyoshi Y, Kataoka M. A prospective longitudinal study comparing a radical retropubic prostatectomy and permanent prostate brachytherapy regarding the health-related quality of life for localized prostate cancer. Jpn J Clin Oncol. 2008 Jul;38(7):480-5. doi: 10.1093/jjco/hyn059. Epub 2008 Jul 11.</citation>
    <PMID>18621847</PMID>
  </results_reference>
  <results_reference>
    <citation>Namiki S, Satoh T, Baba S, Ishiyama H, Hayakawa K, Saito S, Arai Y. Quality of life after brachytherapy or radical prostatectomy for localized prostate cancer: a prospective longitudinal study. Urology. 2006 Dec;68(6):1230-6. Epub 2006 Dec 4.</citation>
    <PMID>17141839</PMID>
  </results_reference>
  <results_reference>
    <citation>Jo Y, Junichi H, Tomohiro F, Yoshinari I, Masato F. Radical prostatectomy versus high-dose rate brachytherapy for prostate cancer: effects on health-related quality of life. BJU Int. 2005 Jul;96(1):43-7.</citation>
    <PMID>15963118</PMID>
  </results_reference>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2008</study_first_submitted>
  <study_first_submitted_qc>October 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2008</study_first_posted>
  <last_update_submitted>October 21, 2008</last_update_submitted>
  <last_update_submitted_qc>October 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>Choi Han Yong</name_title>
    <organization>Samsung Medical Center,Sungkyunkwan University School of Medicine</organization>
  </responsible_party>
  <keyword>quality of life</keyword>
  <keyword>localized prostate cancer</keyword>
  <keyword>FACT-P</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

